Despite the increase in the number of cardiovascular diseases worldwide, the number of new drugs to treat these diseases has been decreasing in the last decade. Current preclinical drug evaluation strategies, which use cell cultures and oversimplified animal models, cannot meet the growing demand for new and effective drugs. In the last decade, the development of microfluidic bioreactors and organ-on-chip systems to improve the drug screening process has been increasing significantly. These systems have shown many advantages over previous preclinical models. Despite all these advantages, keeping the oxygen concentration at the optimal physiological level in microfluidic systems has its own...